• +1-646-491-9876
    • +91-20-67278686

    Search

    E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review H1 2017

    E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review H1 2017

    • Report Code ID: RW0001851069
    • Category Life Sciences
    • No. of Pages 72
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2017'; E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 27 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

    The report 'E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2017' outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Breast Cancer, Lymphoma, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Glioblastoma Multiforme (GBM) , Osteosarcoma, Refractory Multiple Myeloma, Bone Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Follicular Lymphoma, Hematological Tumor, Leukemias, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) , Peripheral T-Cell Lymphomas (PTCL) , Proliferative Vitreoretinopathy (PVR) , Relapsed Multiple Myeloma, Retinoblastoma, Soft Tissue Sarcoma, Uveal Melanoma and Well Differentiated Liposarcoma.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
    - The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
    - The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
    Aileron Therapeutics Inc
    Amgen Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Merck & Co Inc
    Novartis AG
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
    ALRN-6924 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-7209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMG-232 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APG-115 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATSP-7041 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CGM-097 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTX-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-3032 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-5272 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HDM-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    idasanutlin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISA-27 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MI-888 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MMRi-64 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nutlin-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RO-8994 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MDM2 for Breast Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit p53-MDM2 Interaction for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
    Featured News & Press Releases
    Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
    May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
    Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology
    Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology
    Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
    Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH
    Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers
    Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
    Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Aileron Therapeutics Inc, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aileron Therapeutics Inc
    Amgen Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Merck & Co Inc
    Novartis AG

    Request for Sample

    Report Url https://www.reportsweb.com//e3-ubiquitin-protein-ligase-mdm2-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//e3-ubiquitin-protein-ligase-mdm2-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//e3-ubiquitin-protein-ligase-mdm2-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments